drugset / Trial / NCT00442325

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

NCT00442325 ↗

Phase 4 Completed 595 enrolled Viatris Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)

Timeline

Start
2003-01
Primary completion
—
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg —
Subject Atorvastatin Small molecule 20 mg —
Subject Atorvastatin Small molecule 40 mg —
Subject Atorvastatin Small molecule 80 mg —